Abstract:Background: The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is disseminated by respiratory aerosols. The virus uses the spike protein to target epithelial cells by binding to the ACE2 receptor on the host cells. As a result, effective vaccines must target the viral spike glycoprotein. However, the appearance of an Omicron variant with 32 mutations in its spike protein raises questions about the vaccine's efficacy. Vaccines are critical in boosting immunity, lowering COVID-19-related illnesses, reducing the infectious burden on the healthcare system, and reducing economic loss, according to current data. An efficient vaccination campaign is projected to increase innate and adaptive immune responses, offering better protection against SARS-CoV-2 variants. Main body: The presence of altered SARS-CoV-2 variants circulating around the world puts the effectiveness of vaccines already on the market at risk. The problem is made even worse by the Omicron variant, which has 32 mutations in its spike protein. Experts are currently examining the potential consequences of commercial vaccines on variants. However, there are worries about the vaccines' safety, the protection they provide, and whether future structural changes are required for these vaccines to be more effective. As a result of these concerns, new vaccines based on modern technology should be developed to guard against the growing SARS-CoV-2 variations. Conclusion: The choice of a particular vaccine is influenced by several factors including mode of action, storage conditions, group of the vaccinee, immune response mounted, cost, dosage protocol, age, and side effects. Currently, seven SARS-CoV-2 vaccine platforms have been developed. This comprises of inactivated viruses, messenger RNA (mRNA), DNA vaccines, protein subunits, nonreplicating and replicating vector viral-like particles (VLP), and live attenuated vaccines. This review focuses on the SARS-CoV-2 mutations, variants of concern (VOCs), and advances in vaccine technologies.

Novel coronavirus mutations: Vaccine development and challenges

The Challenge of Emerging SARS-CoV-2 Mutants to Vaccine Development

SARS-CoV-2: Mapping its features that made it as a unique virus

Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development

COVID-19 Variants and Vaccine Development

The way of SARS-CoV-2 vaccine development: success and challenges

Scope of SARS-CoV-2 variants, mutations, and vaccine technologies

COVID-19: comprehensive review on mutations and current vaccines

Development of SARS-CoV-2 Vaccine: Challenges and Prospects

The COVID-19 Vaccines: Recent Development, Challenges and Prospects

The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines

Key mutations in the spike protein of SARS‐CoV‐2 affecting neutralization resistance and viral internalization

Coronavirus vaccine development: from SARS and MERS to COVID-19

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic

COVID-19: Coronavirus Vaccine Development Updates

Challenges and Recent Advancements in COVID-19 Vaccines

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

COVID-19 mutations: An overview